TBA-7371

Partners: Foundation for Neglected Disease Research, Bill & Melinda Gates Medical Research Institute

Background:

The enzyme DprE1 is involved in the synthesis of arabinans which are an essential part of mycobacterial cell walls. This is a new target and these inhibitors are active against M.tb. strains resistant to known TB drugs. TBA-7371 has demonstrated in vivo efficacy and a thus far acceptable safety profile.

Phase 2

Trial Components